Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Pediatr Int ; 61(7): 720-725, 2019 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-31102555

RESUMEN

BACKGROUND: Laboratory data in children with newly diagnosed inflammatory bowel disease (IBD) have been reported from Europe and North America, but not Asia. The aim of this study was to clarify laboratory data in Japanese children with newly diagnosed IBD, and to compare them with those in Western reports. METHODS: We retrospectively reviewed patients <16 years old, newly diagnosed with ulcerative colitis (UC) or Crohn's disease (CD) at Kurume University Hospital between January 2008 and December 2015. RESULTS: UC and CD patients numbered 31 and 15, respectively. The percentages of patients with normal values for hemoglobin (Hb), platelet count (Plt), albumin (Alb), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) in the UC and CD groups were 45% and 47%; 68% and 53%; 84% and 40%; 81% and 7%; and 35% and 0%, respectively. The frequency of normal results for these five tests were similar to Western findings except for the greater frequency of normal CRP in UC. Alb and ESR differed significantly between UC and CD in both mild and moderate-severe cases. Plt, Alb, CRP, and ESR differed significantly between diseases in late-onset IBD, whereas early onset IBD showed no differences. In UC, ESR correlated positively, while Hb and Alb correlated negatively, with disease activity. In CD, CRP and ESR correlated positively with activity. CONCLUSIONS: The proportion of Japanese children with IBD having normal values at diagnosis was mostly similar to that in Western reports. In early onset cases, UC parameters may be similar to CD. Of the five tests, ESR was particularly indicative of disease activity at diagnosis in both pediatric UC and CD.


Asunto(s)
Biomarcadores/sangre , Colitis Ulcerosa/diagnóstico , Enfermedad de Crohn/diagnóstico , Adolescente , Niño , Preescolar , Colitis Ulcerosa/sangre , Enfermedad de Crohn/sangre , Femenino , Humanos , Japón , Masculino , Estudios Retrospectivos , Mundo Occidental
2.
J Gastroenterol Hepatol ; 33(1): 264-269, 2018 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-28452067

RESUMEN

BACKGROUND AND AIM: Few studies of zinc monotherapy for presymptomatic Wilson disease have focused on young children. We therefore evaluated long-term efficacy and safety of zinc monotherapy for such children and established benchmarks for maintenance therapy. METHODS: We retrospectively and prospectively examined children under 10 years old with presymptomatic Wilson disease who received zinc monotherapy from time of diagnosis at 12 participating pediatric centers in Japan. RESULTS: Twenty-four patients met entry criteria. Aspartate aminotransferase and alanine aminotransferase decreased significantly beginning 1 month after initiation of treatment and usually remained under 50 U/L from 1 to 8 years of treatment. Twenty four-hour urinary copper decreased significantly at 6 months and usually remained under 75 µg/day and between 1 and 3 µg/kg/day for the remainder of the study. All patients continued to take zinc, and none became symptomatic. In patients under 6 years old who received 50 mg/day of zinc as an initial dose, aspartate aminotransferase and alanine aminotransferase significantly decreased at 1 month after initiation of treatment, as did γ-glutamyltransferase and 24-h urinary copper at 6 months. CONCLUSIONS: To our knowledge, this is the first multicenter study of zinc monotherapy for young children with presymptomatic Wilson disease. Such monotherapy proved highly effective and safe. Maintaining normal transaminase values (or values under 50 U/L when normalization is difficult) and 24-h urinary copper excretion between 1 and 3 µg/kg/day and under 75 µg/day is a reasonable goal. An initial dose of 50 mg/day is appropriate for patients under 6 years old.


Asunto(s)
Degeneración Hepatolenticular/tratamiento farmacológico , Zinc/administración & dosificación , Niño , Preescolar , Femenino , Estudios de Seguimiento , Humanos , Japón , Masculino , Estudios Prospectivos , Estudios Retrospectivos , Factores de Tiempo , Resultado del Tratamiento
3.
BMC Gastroenterol ; 16: 10, 2016 Jan 28.
Artículo en Inglés | MEDLINE | ID: mdl-26822028

RESUMEN

BACKGROUND: Although deleterious mutations in interleukin-10 and its receptor molecules cause severe infantile-onset inflammatory bowel disease, there are no reports of mutations affecting this signaling pathway in Japanese patients. Here we report a novel exonic mutation in the IL10RA gene that caused unique splicing aberrations in a Japanese patient with infantile-onset of inflammatory bowel disease in association with immune thrombocytopenic purpura and a transient clinical syndrome mimicking juvenile myelomonocytic leukemia. CASE PRESENTATION: A Japanese boy, who was the first child of non-consanguineous healthy parents, developed bloody diarrhea, perianal fistula, and folliculitis in early infancy and was diagnosed with inflammatory bowel disease. He also developed immune thrombocytopenic purpura and transient features mimicking juvenile myelomonocytic leukemia. The patient failed to respond to various treatments, including elemental diet, salazosulfapyridine, metronidazole, corticosteroid, infliximab, and adalimumab. We identified a novel mutation (c.537G > A, p.T179T) in exon 4 of the IL10RA gene causing unique splicing aberrations and resulting in lack of signaling through the interleukin-10 receptor. At 21 months of age, the patient underwent allogeneic hematopoietic stem cell transplantation and achieved clinical remission. CONCLUSIONS: We describe a novel exonic mutation in the IL10RA gene resulting in infantile-onset inflammatory bowel disease. This mutation might also be involved in his early-onset hematologic disorders. Physicians should be familiar with the clinical phenotype of IL-10 signaling defects in order to enable prompt diagnosis at an early age and referral for allogeneic hematopoietic stem cell transplantation.


Asunto(s)
Exones , Enfermedades Inflamatorias del Intestino/genética , Interleucina-10/genética , Mutación , Empalme del ARN , Trasplante de Células Madre Hematopoyéticas , Humanos , Lactante , Enfermedades Inflamatorias del Intestino/cirugía , Masculino , Polimorfismo de Nucleótido Simple , Inducción de Remisión/métodos
5.
Sci Rep ; 10(1): 6752, 2020 04 21.
Artículo en Inglés | MEDLINE | ID: mdl-32317688

RESUMEN

Few reports describe oxysterols in healthy children or in children with liver disease. We aimed to determine whether developmental changes in urinary and serum oxysterols occur during childhood, and to assess whether oxysterols might be biomarkers for pediatric liver disease. Healthy children enrolled as subjects (36 and 35 for urine and serum analysis, respectively) included neonates, infants, preschoolers, and school-age children, studied along with 14 healthy adults and 8 children with liver disease. We quantitated 7 oxysterols including 4ß-, 20(S)-, 22(S)-, 22(R)-, 24(S)-, 25-, and 27-hydroxycholesterol using liquid chromatography/electrospray ionization-tandem mass spectrometry. Urinary total oxysterols were significantly greater in neonates than in infants (P < 0.05), preschoolers (P < 0.001), school-age children (P < 0.001), or adults (P < 0.001), declining with age. Serum total oxysterols in neonates were significantly lower than in infants (P < 0.05), preschoolers (P < 0.001), school-age children (P < 0.05), or adults (P < 0.01). Compared with healthy children, total oxysterols and 24(S)-hydroxycholesterol in liver disease were significantly increased in both urine (P < 0.001 and P < 0.001, respectively) and serum (P < 0.001 and P < 0.05, respectively). Oxysterols in liver disease, particularly 24(S)-hydroxycholesterol, were greater in urine than serum. Oxysterols change developmentally and might serve as a biomarker for pediatric liver disease. To our knowledge, this is the first such report.


Asunto(s)
Atresia Biliar/diagnóstico , Quiste del Colédoco/diagnóstico , Colestasis Intrahepática/diagnóstico , Hepatitis Autoinmune/diagnóstico , Fallo Hepático Agudo/diagnóstico , Oxiesteroles , Adolescente , Adulto , Factores de Edad , Atresia Biliar/sangre , Atresia Biliar/patología , Atresia Biliar/orina , Biomarcadores/sangre , Biomarcadores/orina , Estudios de Casos y Controles , Niño , Preescolar , Quiste del Colédoco/sangre , Quiste del Colédoco/patología , Quiste del Colédoco/orina , Colestasis Intrahepática/sangre , Colestasis Intrahepática/patología , Colestasis Intrahepática/orina , Femenino , Hepatitis Autoinmune/sangre , Hepatitis Autoinmune/patología , Hepatitis Autoinmune/orina , Humanos , Lactante , Recién Nacido , Hígado/metabolismo , Hígado/patología , Fallo Hepático Agudo/sangre , Fallo Hepático Agudo/patología , Fallo Hepático Agudo/orina , Masculino , Persona de Mediana Edad , Oxiesteroles/sangre , Oxiesteroles/orina , Espectrometría de Masa por Ionización de Electrospray
6.
Medicine (Baltimore) ; 97(42): e12879, 2018 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-30335007

RESUMEN

RATIONALE: Nonalcoholic fatty liver disease (NAFLD), among the commonest chronic liver disorders in children and adolescents, is considered a reflection of the current obesity epidemic in children and adults. This liver disease has been linked with various metabolic disorders, but not with prolactinoma (PRLoma). PATIENT CONCERNS: A 13-year-old Japanese girl manifested obesity, serum transaminase and γ-glutamyltransferase elevations, and amenorrhea. Abdominal ultrasonography showed fatty liver. Her serum prolactin concentration was elevated, and cranial magnetic resonance imaging showed a pituitary mass consistent with macroadenoma. DIAGNOSES: NAFLD and PRLoma. INTERVENTIONS AND OUTCOMES: After the patient's NAFLD failed to respond to diet and exercise, cabergoline treatment of the PRLoma decreased body weight, serum transaminase and γ-glutamyltransferase elevations, and ultrasonographic fatty liver grade as the tumor became smaller. LESSONS: Physicians should consider the possibility of PRLoma when diet and exercise fail to improve fatty liver disease in a patient with endocrine symptoms such as amenorrhea.


Asunto(s)
Enfermedad del Hígado Graso no Alcohólico/complicaciones , Neoplasias Hipofisarias/etiología , Prolactinoma/etiología , Adolescente , Femenino , Humanos
7.
Medicine (Baltimore) ; 97(41): e12811, 2018 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-30313113

RESUMEN

INTRODUCTION: Chronic nonspecific multiple ulcers of the small intestine (CNSU), an entity with female preponderance and manifestations including anemia and hypoproteinemia reflecting persistent gastrointestinal bleeding and intestinal protein loss, has been considered idiopathic. Umeno et al recently reported that CNSU is caused by loss-of-function mutations in the solute carrier organic anion transporter family member 2A1 gene (SLCO2A1) encoding a prostaglandin transporter, renaming the disorder "chronic enteropathy associated with SLCO2A1 gene mutation" (CEAS). Treatments for chronic enteropathies such as inflammatory bowel disease, including 5-aminosalicylic acid, corticosteroids, azathioprine, and anti-tumor necrosis factor-α antibody, often are ineffective in CEAS, which frequently requires surgery. CASE PRESENTATION: A 14-year-old girl had refractory anemia and hypoproteinemia for more than 2 years. Video capsule endoscopy showed nonspecific jejunal and ileal ulcers with varied sizes and shapes. She was diagnosed with CEAS resulting from compound heterozygous mutation of the SLCO2A1 gene. After corticosteroid treatment without improvement, azathioprine treatment improved her anemia and edema as hemoglobin and serum protein increased. Video capsule endoscopy 1 year after initiation of azathioprine showed improvement of small intestinal ulcers. CONCLUSION: Physicians should consider CEAS in patients with refractory anemia, hypoproteinemia, and multiple small intestinal ulcers. Why our patient responded to azathioprine but not to corticosteroids is unclear, but azathioprine might benefit some other patients with CEAS.


Asunto(s)
Azatioprina/uso terapéutico , Inmunosupresores/uso terapéutico , Intestino Delgado , Transportadores de Anión Orgánico/genética , Úlcera Péptica/tratamiento farmacológico , Úlcera Péptica/genética , Adolescente , Endoscopía Capsular , Enfermedad Crónica , Femenino , Humanos , Enfermedades del Íleon/tratamiento farmacológico , Enfermedades del Íleon/genética , Enfermedades del Yeyuno/tratamiento farmacológico , Enfermedades del Yeyuno/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA